医学
止血
外科
随机对照试验
血肿
绷带
显著性差异
安慰剂
内科学
病理
替代医学
作者
Şevket Görgülü,Tuğrul Norgaz,İlke Sipahi
摘要
Background We planned a three arm randomized study to evaluate the safety and efficacy of a new blood stopper, Ankaferd blood stopper (ABS) along with short‐time compression, compared to either short‐time compression with conventional sterile gauzes (CSG) or with a TR band after transradial (TRA) procedures. Methods The Ankaferd blood stopper as a new strategy to avoid early complications. After transradial procedures (ABS transradial) trial is designed in a prospective, randomized, placebo‐controlled fashion and registered with http://clinicaltrials.gov (NCT02982733). Six hundred and thirty patients were randomized into three arms in a 1:1:1 fashion corresponding to three different strategies of patent hemostasis techniques after diagnostic or interventional catheterization. Results One (0.49%) patient in the CSG group and one patient (0.48%) in the TR Band group developed RAO at the end of the hemostasis, compared with 0 (0%) in the ABS group. At 30 days follow‐up none of the groups had any patients with RAO. As a secondary end‐points the difference was not statistically significant regarding hematoma among the three groups ( P = 0.70). Bleeding during deflation of the TR Band or removal of the elastic bandage occurred in 55 patients (26.96%) in the CSG group and in 56 (27.31%) patients in the TR Band group compared to 19 patients (9.40%) in the ABS group ( P < 0.001). Conclusion Ankaferd blood stopper is a promising device for use in patent hemostasis, with no evidence on RAO at short‐term or long term and with reduced risk of re‐bleeding at the end of hemostasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI